PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

摘要: Purpose: It has been reported that activating KRAS mutations negatively affect response to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. The mutation status of signaling molecules downstream the EGFR target is thus crucial predict clinical benefit EGFR-targeted therapies. Other mechanisms resistance inhibitors could involve other main effector pathway, i.e., PI3K/PTEN/AKT pathway. Experimental Design: We analyzed PIK3CA and a large group ( n = 200) chemorefractory cancers treated with cetuximab (Erbitux) monotherapy or combination irinotecan, correlated outcome. Results: Twenty-three (12%) 200 samples carried 1 included our assay. found no correlation between presence impaired cetuximab. Conclusions: Our findings do not provide any evidence for strong role as single marker determining